EDAP

EDAP TMS
EDAP

$3.05
0.97%

Market Cap: $113M

 

About: Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Employees: 307

0
Funds holding %
of 6,710 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

8% less funds holding

Funds holding: 37 [Q1] → 34 (-3) [Q2]

9.82% less ownership

Funds ownership: 52.81% [Q1] → 42.99% (-9.82%) [Q2]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

39% less capital invested

Capital invested by funds: $143M [Q1] → $86.8M (-$56.6M) [Q2]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

71% less call options, than puts

Call options by funds: $378K | Put options by funds: $1.29M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$19
523%
upside
Avg. target
$19
523%
upside
High target
$19
523%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
30% 1-year accuracy
39 / 128 met price target
523%upside
$19
Buy
Reiterated
29 Aug 2024
HC Wainwright & Co.
Swayampakula Ramakanth
30% 1-year accuracy
39 / 128 met price target
523%upside
$19
Buy
Reiterated
22 Jul 2024

Financial journalist opinion

Based on 4 articles about EDAP published over the past 30 days

Neutral
GlobeNewsWire
4 months ago
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting
Final results demonstrate a significantly higher salvage treatment free survival rate (STFS) at 30 months of 89.6% in the HIFU-treated arm versus 86.2% in patients who underwent radical prostatectomy (RP) Functional evaluation criteria show better results with respect to urinary continence and erectile function in patients receiving HIFU therapy versus patients receiving RP Final study results were presented during a plenary session of the AUA focused on paradigm-shifting and practice-changing clinical trials in urology HIFI Study is the largest clinical study ever conducted evaluating treatment outcomes with Focal One robotic HIFU, enrolling a total of 3,328 prospective patients, including 1,967 consecutive HIFU patients and 1,361 RP patients across 46 centers LYON, France, May 6, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced a recent presentation highlighting the positive, final results from a large, prospective, multicenter, non-inferiority study, the HIFI Study, comparing Focal One® high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) at the 119th American Urological Association Annual Meeting (AUA 2024), which took place from May 3-6, 2024, in San Antonio, Texas, USA. Professor Pascal Rischmann of Rangueil University Hospital in Toulouse, France, and lead investigator of the HIFI Study, highlighted the final results from the study during an oral presentation at the AUA plenary session, “Paradigm-shifting, Practice-changing Clinical Trials in Urology”.
EDAP Announces Positive Final Results from the HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy During Plenary Session at the 119th American Urological Association (AUA) Annual Meeting